Download PDF
Thromb Haemost 1988; 60(01): 079-082
DOI: 10.1055/s-0038-1647639
Original Article
Schattauer GmbH Stuttgart

Circulating Osteocalcin During Oral Anticoagulant Therapy

L J M van Haarlem
The Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
,
M H J Knapen
The Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
,
K Hamulyák
The Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
,
C Vermeer
The Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 16 February 1988

Accepted after revision 14 April 1988

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In this paper we present the following observations:

1) In sheep vitamin K-antagonists like phenprocoumon induce a decrease of the serum levels of osteocalcin (bone Gla-protein) and of the affinity of the circulating osteocalcin for hydroxyapatite.

2) In sheep vitamin K counteracts the effect of phen-procoumon on the blood coagulation system, but not that on the osteocalcin production.

3) In human subjects vitamin K-antagonists also lead to decreased levels of serum osteocalcin and a low affinity of the protein for hydroxyapatite.

4) These two variables reached steady-state levels within 24 h after the start of oral anticoagulant treatment and - at continu-ation of the therapy - they remained low for at least several years.

Key words

Osteocalcin - Vitamin K - Oral anticoagulants - Gammacar - boxyglutamic acid - Blood coagulation - Bone
 

  • References

  • 1 Price PA, Williamson MK, Lothringer JW. Origin of the vitamin Independent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 1981; 24: 12760-12766
    PubMedGoogle Scholar
  • 2 Nishimoto SK, Price PA. Secretion of the vitamin K-dependent protein of bone by rat osteosarcoma cells. Evidence for an intracellular precursor J Biol Chem 1980; 255: 6579-6583
    PubMedGoogle Scholar
  • 3 Price PA, Nishimoto SK. Radioimmunoassay for the vitamin independent protein of bone and its discovery in plasma. Proc Natl Acad Sci USA 1980; 77: 2234-2238
    CrossrefPubMedGoogle Scholar
  • 4 Pan LC, Price PA. The propeptide of rat bone gamma-carboxy-glutamic acid protein shares homology with other vitamin K-dependent protein precursors. Proc Natl Acad Sci USA 1985; 82: 6209-6213
    PubMedGoogle Scholar
  • 5 Roncaglioni MC, Soute BA M, de Boer-van den Berg MA G, Vermeer C. Warfarin-induced accumulation of vitamin K-dependent proteins. Comparison between hepatic and non-hepatic tissues Biochem Biophys Res Commun 1983; 114: 991-997
    CrossrefPubMedGoogle Scholar
  • 6 de Boer-van den Berg MA G, Thijssen HH W, Vermeer C. The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin-K dependent carboxylase in various tissues of the rat. Biochim Biophys Acta 1986; 884: 150-157
    CrossrefPubMedGoogle Scholar
  • 7 Van Haarlem LJ M, Ulrich MM W, Hemker HC, Soute BA M, Vermeer C. Isolation and partial characterization of a vitamin K-dependent carboxylase from bovine aortae. Biochem J 1987; 254: 251-255
    PubMedGoogle Scholar
  • 8 Price PA, Williamson MK. Effects of warfarin on bone. Studies on the vitamin K-dependent protein of rat bone J Biol Chem 1981; 256: 12754-12759
    PubMedGoogle Scholar
  • 9 Price PA, Kaneda Y. Vitamin K counteracts the effect of warfarin in liver but not in bone. Thromb Res 1987; 46: 121-131
    CrossrefPubMedGoogle Scholar
  • 10 Ulrich MM W, Knapen MH J, Herrmann-Erlee MP M, Vermeer C. Vitamin K is no antagonist for the action of warfarin in rat osteosarcoma UMR 106. Thrombos Res 1988; 50: 27-32
    PubMedGoogle Scholar
  • 11 Menon RK, Gill DS, Thomas M, Kernoff PB A, Dandona P. Impaired carboxylation of osteocalcin in warfarin-treated patients. J Clin Endocrinol Metab 1987; 64: 59-61
    CrossrefPubMedGoogle Scholar
  • 12 Vermeer C, Soute BA M, Hendrix H, de Boer-van den Berg MA G. Decarboxylated bone Gla-protein as a substrate for hepatic vitamin K-dependent carboxylase. FEBS Lett 1984; 165: 16-20
    CrossrefPubMedGoogle Scholar
  • 13 Poser JW, Price PA. A method for decarboxylation of gammacar-boxyglutamic acid in protein. Properties of the decarboxylated gammacarboxyglutamic acid protein from calf bone J Biol Chem 1979; 254: 431-436
    PubMedGoogle Scholar
  • 14 Hemker HC, Veltkamp JJ, Loeliger EA. Kinetic aspects of the interaction of blood enzymes. III. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency. Thromb Diath Haemorrh 1968; 19: 346-363
    PubMedGoogle Scholar
  • 15 Vermeer C, Soute BAM, Hemker HC. A new method for the preparation of artificial factor II reagents from normal human and bovine plasma. Thromb Res 1977; 10: 495-507
    CrossrefPubMedGoogle Scholar
  • 16 Patterson-Allen P, Brautigam CE, Grindeland RE, Asling CW, Callahan PX. A specific radioimmunoassay for osteocalcin with advantageous species cross-reactivity. Analyt Biochem 1982; 120: 1-7
    CrossrefPubMedGoogle Scholar
  • 17 Reid IR, Chapman GE, Fraser TR C, Davies AD, Surus AS, Meyer J, Huq NC, Ibbertson HK. Low serum osteocalcin levels in glucocorticoid-treated asthmatics. J Clin Endocrinol Metab 1986; 62: 379-383
    CrossrefPubMedGoogle Scholar
  • 18 de Boer-van den Berg MA G, Thijssen HH W, Vermeer C. The in vivo effects of oral anticoagulants in man: comparison between liver and non-hepatic tissues. Thromb Haemostas 1988; 59: 147-150
    PubMedGoogle Scholar